Staar Surgical rises after Stifel upgrades to 'buy'
STAA•Stifel upgraded Staar Surgical to “buy” from “hold” and raised its price target to $31 from $28, citing sales growth potential in China and recovering international demand.
1. Stifel raises rating
Stifel said adoption of Staar Surgical’s EVO+ lens in China and recovering international demand could support sales growth, and upgraded the stock to “buy” from “hold.” The brokerage raised its price target to $31 from $28, which it said was 49% above the stock’s last close.
